New IV drug shows promise for severe Post-Birth depression
NCT ID NCT02614547
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an experimental drug called SAGE-547, given as an IV infusion, in 21 adult women with severe postpartum depression. The goal was to see if it could quickly reduce depression symptoms compared to a placebo. The trial was randomized and double-blind, meaning neither patients nor doctors knew who got the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAGE-547 (a drug given as an IV infusion)
- What this could lead to
- If it works, this could offer a fast-acting treatment option for women with severe postpartum depression, potentially easing symptoms within days.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE POSTPARTUM DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sage Investigational Site
Atlanta, Georgia, 30342, United States
-
Sage Investigational Site
Worcester, Massachusetts, 01655, United States
-
Sage Investigational Site
Chapel Hill, North Carolina, 27514, United States
-
Sage Investigational Site
Philadelphia, Pennsylvania, 19104, United States